CRAVE Study to investigate semaglutide and tirzepatide impact on food cravings and diet quality in overweight/obese adults

While GLP-1 receptor agonists like semaglutide and tirzepatide are highly effective for weight loss in individuals with overweight or obesity, their specific effects on diet quality and food cravings are less understood. Current treatments primarily focus on weight reduction, but understanding how these medications influence eating behaviors beyond simple caloric restriction is crucial. This study aims to fill this literature gap, providing insights into the broader impact of GLP-1RAs on dietary habits and subjective eating experiences.

The CRAVE Study is a prospective observational study designed to monitor up to 150 adult participants with overweight or obesity over 24 weeks. Participants using GLP-1 receptor agonists, specifically semaglutide and tirzepatide, will be assessed at 0, 12, and 24 weeks. Researchers will use questionnaires and dietary records to measure changes in primary endpoints including diet quality, disordered eating, food cravings, and hunger. The study is conducted with Seen Medical Group at Knownwell Health Clinic.